Claims for Patent: 9,616,028

Summary for Patent: 9,616,028

Title:	Bilayer tablet formulations
Abstract:	The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
Inventor(s):	Abebe; Admassu (Princeton, NJ), Martin; Kyle (Princeton, NJ), Patel; Jatin M. (Princeton, NJ), Desai; Divyakant (Princeton, NJ), Timmins; Peter (Moreton, GB)
Assignee:	AstraZeneca AB (Sodertalje, SE) AstraZeneca UK Limited (London, GB)
Application Number:	14/706,077
Patent Claims:	1. A bilayer tablet comprising: (1) a first layer wherein the first layer is a metformin hydrochloride extended release formulation comprising 40-82% metformin hydrochloride, 3-5% sodium carboxymethyl cellulose; 15-40% hydroxypropyl methylcellulose; 0.1-0.75% magnesium stearate; and 0-2% silicon dioxide or 0-1.5% colloidal silicon dioxide, said percentages based on the total weight of the first layer; (2) a second layer wherein the second layer is a sodium dependent glucose transporter-2 inhibitor (SGLT2 inhibitor) formulation comprising 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 14-18% lactose anhydrous; 50-80% microcrystalline cellulose; 2-6% crospovidone; 0.5-2.5% silicon dioxide; and 0.5-2% magnesium stearate, said percentages based on the total weight of the second layer; and (3) a film coating that covers the first layer and the second layer comprising polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. 2. The bilayer tablet according to claim 1 wherein the total weight of the second layer is 300 mgs to 400 mgs. 3. The bilayer tablet according to claim 1 wherein the first layer further comprises microcrystalline cellulose. 4. The bilayer tablet according to claim 1 wherein the first layer further comprises 5-15% microcrystalline cellulose, said percentage based on the total weight of the first layer. 5. The bilayer tablet according to claim 1 wherein the second layer comprises: 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 14-18% lactose anhydrous; 72-80% microcrystalline cellulose; 2-6% crospovidone; 0.5-2.5% silicon dioxide; and 0.5-1.5% magnesium stearate; said percentages based on the total weight of the second layer. 6. The bilayer tablet according to claim 1 wherein (1) the first layer comprises 42-82% metformin hydrochloride; 3-5% sodium carboxymethyl cellulose; 15-40% hydroxypropyl methylcellulose; 0.75-1.25% silicon dioxide or 0.25-0.75% colloidal silicon dioxide; and 0.1-0.75% magnesium stearate, said percentages based on the total weight of the first layer; and (2) the second layer is 300 mgs to 400 mgs. 7. The bilayer tablet according to claim 6 wherein the first layer further comprises 5-15% microcrystalline cellulose, said percentage based on the total weight of the first layer. 8. The bilayer tablet according to claim 6 wherein the second layer comprises: 0.5-4% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 14-18% lactose anhydrous; 72-80% microcrystalline cellulose; 2-6% crospovidone; 0.5-2.5% silicon dioxide; and 0.5-1.5% magnesium stearate; said percentages based on the total weight of the second layer.